In:
Frontiers in Pharmacology, Frontiers Media SA, Vol. 15 ( 2024-3-20)
Abstract:
Cognitive deficits and behavioral disorders such as anxiety and depression are common manifestations of Alzheimer’s disease (AD). Our previous work demonstrated that Trichostatin A (TSA) could alleviate neuroinflammatory plaques and improve cognitive disorders. AD, anxiety, and depression are all associated with microglial inflammation. However, whether TSA could attenuate anxiety- and depression-like behaviors in APP/PS1 mice through anti-inflammatory signaling is still unclearly. Methods: In the present study, all mice were subjected to the open field, elevated plus maze, and forced swim tests to assess anxiety- and depression-related behaviors after TSA administration. To understand the possible mechanisms underlying the behavioral effects observed, CST7 was measured in the hippocampus of mice and LPS-treated BV2 microglia. Results: The results of this study indicated that TSA administration relieved the behaviors of depression and anxiety in APP/PS1 mice, and decreased CST7 levels in the hippocampus of APP/PS1 mice and LPS-induced BV2 cells. Conclusion: Overall, these findings support the idea that TSA might be beneficial for reducing neurobehavioral disorders in AD and this could be due to suppression of CST7 -related microglial inflammation.
Type of Medium:
Online Resource
ISSN:
1663-9812
DOI:
10.3389/fphar.2024.1333235
DOI:
10.3389/fphar.2024.1333235.s001
DOI:
10.3389/fphar.2024.1333235.s002
DOI:
10.3389/fphar.2024.1333235.s003
DOI:
10.3389/fphar.2024.1333235.s004
DOI:
10.3389/fphar.2024.1333235.s005
DOI:
10.3389/fphar.2024.1333235.s006
Language:
Unknown
Publisher:
Frontiers Media SA
Publication Date:
2024
detail.hit.zdb_id:
2587355-6
SSG:
15,3
Permalink